| Pharmaceuticals - APIs and Formulations | Manufacturing and export of cephalosporin APIs and finished dosage formulations including sterile products. | USFDA compliant facilities, proprietary NCE ownership, extensive R&D, global marketing networks, and regulatory compliance. | Global pharmaceutical companies and healthcare providers (B2B, B2C). | Sterile cephalosporin APIs and novel antibiotic formulations. | 922 | 100 | Sales of bulk APIs and formulations under contracts and direct marketing; exports form majority revenue base. | Contractual pricing, volume-based sales, and long-term supply agreements. | Global anti-infective demand, novel drug ownership, regulatory approvals, capacity expansions, strategic acquisitions. | Orblicef (Enmetazobactam), other cephalosporin APIs |
